5F-PB-22
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H21FN2O2 |
| Molar mass | 376.42 g/mol |
| 3D model (Jmol) | |
|
|
|
|
5F-PB-22 (5F-QUPIC or Quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate) is a designer drug which acts as a cannabinoid agonist.[1] The structure of 5F-PB-22 appears to have been designed with an understanding of structure-activity relationships within the indole class of cannabinoids.[2]
Pharmacology[edit]
5F-PB-22 acts as a full agonist with a binding affinity of 0.468nM at CB1 and 0.633nM at CB2 cannabinoid receptors.[3]
Legal Status[edit]
As of October 2015 5F-PB-22 is a controlled substance in China.[4]
In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States after several deaths were associated with its use.[5][6]
In the United Kingdom (as of May 2016), previously unregulated substances deemed to be psychoactive are now controlled by the Psychoactive Substances Act. Consequently, the sale, distribution, import, and purchase of 5F-PB-22 is banned.[7]
See also[edit]
References[edit]
- ^ Banister, S. D.; Stuart, J.; Kevin, R. C.; Edington, A.; Longworth, M.; Wilkinson, S. M.; Beinat, C.; Buchanan, A. S.; Hibbs, D. E.; Glass, M.; Connor, M.; McGregor, I. S.; Kassiou, M. (2015). "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 150508124201002. doi:10.1021/acschemneuro.5b00107. PMID 25921407.
- ^ "5F-PB-22". Forendex. Retrieved 24 June 2015.
- ^ Hess, Cornelius; Schoeder, ClaraT.; Pillaiyar, Thanigaimalai; Madea, Burkhard; Müller, ChristaE. (1 July 2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. ISSN 1860-8965. PMC 4929166
. PMID 27429655. - ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- ^ Behonick, G; Shanks, K. G.; Firchau, D. J.; Mathur, G; Lynch, C. F.; Nashelsky, M; Jaskierny, D. J.; Meroueh, C (2014). "Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22". Journal of analytical toxicology. 38 (8): 559–62. doi:10.1093/jat/bku048. PMC 4334789. PMID 24876364.
- ^ Jordan Trecki; Roy R. Gerona; Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine. 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
- ^ "Psychoactive Substances Act 2016 — UK Parliament". services.parliament.uk. Retrieved 2016-11-02.
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
